^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

CD19 expression

i
Other names: CD19, CD19 Molecule, B-Lymphocyte Surface Antigen B4, T-Cell Surface Antigen Leu-12, Differentiation Antigen CD19, B-Lymphocyte Antigen CD19, CD19 Antigen, CVID3, B4
Entrez ID:
Related biomarkers:
Phase 1
University of Pennsylvania
Recruiting
Last update posted :
04/19/2024
Initiation :
05/06/2021
Primary completion :
05/01/2036
Completion :
05/01/2036
ALK • BCL2 • CD19 • BCL6
|
CD19 expression • BCL6 rearrangement • BCL2 rearrangement
|
huCART19 • huCART19-IL18
Phase 1
National Cancer Institute (NCI)
Completed
Last update posted :
04/19/2024
Initiation :
08/04/2010
Primary completion :
03/08/2024
Completion :
04/02/2024
CD19
|
CD19 expression
Phase 2
National Cancer Institute (NCI)
Suspended
Last update posted :
04/18/2024
Initiation :
12/04/2020
Primary completion :
06/30/2028
Completion :
06/30/2028
CD19
|
CD19 expression
|
Opdivo (nivolumab) • cytarabine • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • Blincyto (blinatumomab) • methotrexate • vincristine • dexamethasone • leucovorin calcium • Oncaspar liquid (pegaspargase) • mercaptopurine delayed release (DR6MP) • mercaptopurine • thioguanine • Hemady (dexamethasone tablets) • Starasid (cytarabine ocfosfate) • cyclophosphamide intravenous • dexamethasone injection
Phase 1/2
National Cancer Institute (NCI)
Recruiting
Last update posted :
04/16/2024
Initiation :
12/28/2022
Primary completion :
07/01/2027
Completion :
07/01/2029
CD19 • CD22
|
CD19 expression • CD22 expression
|
cyclophosphamide • fludarabine IV
Phase 1
Hoffmann-La Roche
Recruiting
Last update posted :
04/12/2024
Initiation :
02/18/2022
Primary completion :
04/30/2025
Completion :
04/30/2025
CD20 • CD19
|
CD20 expression • CD19 expression
|
Gazyva (obinutuzumab) • Actemra IV (tocilizumab) • Columvi (glofitamab-gxbm) • RG6333
Phase 1
National Cancer Institute (NCI)
Recruiting
Last update posted :
04/09/2024
Initiation :
03/26/2018
Primary completion :
12/01/2025
Completion :
12/31/2040
CD19 • CD22
|
CD19 expression • CD22 expression
|
cyclophosphamide • fludarabine IV • CD19/CD22 CAR T-cells • cyclophosphamide intravenous
Phase N/A
University Hospital, Montpellier
Not yet recruiting
Last update posted :
04/08/2024
Initiation :
04/08/2024
Primary completion :
04/08/2026
Completion :
04/08/2026
CD20
|
CD19 expression
Phase 2
Institute of Hematology and Blood Transfusion, ...
Completed
Last update posted :
04/04/2024
Initiation :
05/09/2019
Primary completion :
02/29/2024
Completion :
02/29/2024
ABL1 • BCR • CD19
|
CD19 expression
|
Blincyto (blinatumomab)
Phase 1
Baylor College of Medicine
Recruiting
Last update posted :
04/02/2024
Initiation :
02/01/2014
Primary completion :
12/01/2024
Completion :
02/01/2036
CD19
|
CD19 positive • CD19 expression
|
cyclophosphamide • fludarabine IV • CD19 specific CAR T cell therapy • cyclophosphamide intravenous
Phase 1
University of Pennsylvania
Recruiting
Last update posted :
04/01/2024
Initiation :
11/13/2023
Primary completion :
10/01/2026
Completion :
10/01/2041
ALK • BCL2 • CD19 • BCL6
|
CD19 expression • BCL6 rearrangement • BCL2 rearrangement
|
huCART19-IL18
Phase 2
Memorial Sloan Kettering Cancer Center
Recruiting
Last update posted :
03/28/2024
Initiation :
03/14/2023
Primary completion :
03/14/2025
Completion :
03/14/2025
CD19
|
CD19 expression
|
lenalidomide • Monjuvi (tafasitamab-cxix)
Phase 1
Hoffmann-La Roche
Recruiting
Last update posted :
03/27/2024
Initiation :
08/13/2019
Primary completion :
03/31/2025
Completion :
03/31/2025
CD20 • CD19
|
CD20 expression • CD19 expression
|
Gazyva (obinutuzumab) • Actemra IV (tocilizumab) • Columvi (glofitamab-gxbm) • englumafusp alfa (RG6076)
Phase 2
Northwestern University
Active, not recruiting
Last update posted :
03/27/2024
Initiation :
06/01/2011
Primary completion :
08/17/2015
Completion :
05/01/2027
CD20 • CD5 • CD52 • FCER2
|
CD19 expression
|
Campath (alemtuzumab) • Arzerra (ofatumumab)
Phase 2
Novartis Pharmaceuticals
Recruiting
Last update posted :
03/25/2024
Initiation :
06/24/2019
Primary completion :
10/19/2027
Completion :
10/19/2027
CD19
|
CD19 expression
|
Kymriah (tisagenlecleucel-T)
Phase 1
Synthekine
Recruiting
Last update posted :
03/21/2024
Initiation :
06/24/2022
Primary completion :
06/24/2026
Completion :
11/01/2026
CD19
|
CD19 expression
|
cyclophosphamide • fludarabine IV • STK-009/SYNCAR-001
Phase N/A
Masonic Cancer Center, University of Minnesota
Active, not recruiting
Last update posted :
03/18/2024
Initiation :
12/18/2018
Primary completion :
02/09/2024
Completion :
06/01/2028
CD19
|
CD19 expression
|
cyclophosphamide • Yescarta (axicabtagene ciloleucel) • Breyanzi (lisocabtagene maraleucel) • Kymriah (tisagenlecleucel-T) • fludarabine IV • Tecartus (brexucabtagene autoleucel) • Abecma (idecabtagene vicleucel) • cyclophosphamide intravenous
Phase 1
Children's Hospital of Fudan University
Active, not recruiting
Last update posted :
03/15/2024
Initiation :
01/09/2020
Primary completion :
10/20/2024
Completion :
07/20/2025
CD19 • CD4
|
CD19 expression
|
cyclophosphamide • fludarabine IV • alloCART-19 cell therapy • cyclophosphamide intravenous
Phase 1
Memorial Sloan Kettering Cancer Center
Recruiting
Last update posted :
03/08/2024
Initiation :
02/02/2021
Primary completion :
01/01/2025
Completion :
01/01/2025
CD20 • CD19
|
CD19 expression
|
Iomab-B (I-131-apamistamab) • 131-I Apamistamab/CAR T-cell (Iomab-ACT) • vadacabtagene leraleucel (JCAR015)
Phase 1/2
Juventas Cell Therapy Ltd.
Not yet recruiting
Last update posted :
03/08/2024
Initiation :
08/31/2024
Primary completion :
12/30/2024
Completion :
12/30/2026
IL6
|
CD19 expression
|
cyclophosphamide • fludarabine IV • HY004
Phase 1
Sumithira Vasu
Recruiting
Last update posted :
03/07/2024
Initiation :
06/30/2022
Primary completion :
12/31/2024
Completion :
12/31/2024
CD20 • CD19 • CD22
|
CD20 positive • CD19 expression
|
cyclophosphamide • fludarabine IV • Anti-CD19/CD20/CD22 CAR T-Cells
Phase 1/2
University of Washington
Recruiting
Last update posted :
03/07/2024
Initiation :
12/02/2020
Primary completion :
03/01/2025
Completion :
03/01/2030
CD4
|
CD19 expression
|
Calquence (acalabrutinib) • Yescarta (axicabtagene ciloleucel)
Phase 2
PETHEMA Foundation
Recruiting
Last update posted :
03/06/2024
Initiation :
11/23/2023
Primary completion :
05/01/2025
Completion :
12/01/2029
KIT • CD19 • CD38 • PTPRC • NCAM1 • CD27 • CD81
|
CD38 expression • CD19 expression • NCAM1 expression • CD27 expression • CD5 overexpression • NCAM1 overexpression
|
Elrexfio (elranatamab-bcmm)
Phase 3
National Cancer Institute (NCI)
Not yet recruiting
Last update posted :
03/05/2024
Initiation :
04/22/2024
Primary completion :
12/01/2030
Completion :
12/01/2030
ABL1 • KIT • PDGFRA • CD19 • PDGFRB • CSF1R
|
CD19 expression
|
dasatinib • imatinib • cytarabine • doxorubicin hydrochloride • cyclophosphamide • Blincyto (blinatumomab) • methotrexate • vincristine • daunorubicin • leucovorin calcium • Oncaspar liquid (pegaspargase) • mercaptopurine • Asparlas (calaspargase pegol-mknl) • thioguanine • Starasid (cytarabine ocfosfate)
Phase 1
Crystal Mackall, MD
Active, not recruiting
Last update posted :
02/28/2024
Initiation :
09/01/2017
Primary completion :
09/01/2025
Completion :
09/01/2035
CD19 • CD22
|
CD19 positive • CD19 expression • CD22 expression
|
cyclophosphamide • fludarabine IV • NKTR-255 • cyclophosphamide intravenous
Phase 1
Dr. Melody Smith, MD, MS
Recruiting
Last update posted :
02/20/2024
Initiation :
08/18/2022
Primary completion :
01/01/2037
Completion :
01/01/2037
CD19 • KMT2A • CRLF2 • CD22 • HLA-DRB1 • HLA-B • HLA-C
|
KMT2A rearrangement • MLL rearrangement • CD19 expression • CRLF2 rearrangement
|
Orca-T • firicabtagene autoleucel (CRG-022)
Phase 1
National Cancer Institute (NCI)
Recruiting
Last update posted :
02/19/2024
Initiation :
08/28/2023
Primary completion :
12/30/2028
Completion :
12/30/2029
BCL2 • BCL6
|
MET expression • CD20 expression • CD19 expression • BCL6 rearrangement • BCL2 rearrangement
|
cyclophosphamide • fludarabine IV
Phase 2
M.D. Anderson Cancer Center
Recruiting
Last update posted :
02/15/2024
Initiation :
07/14/2023
Primary completion :
12/31/2027
Completion :
12/31/2029
CD19 • CD22
|
CD19 expression
|
Rituxan (rituximab) • cytarabine • cyclophosphamide • Blincyto (blinatumomab) • Besponsa (inotuzumab ozogamicin) • vincristine • prednisone • mercaptopurine • Neulasta (pegfilgrastim) • Depocyte (liposomal cytarabine)
Phase 2
Novartis Pharmaceuticals
Completed
Last update posted :
02/13/2024
Initiation :
04/08/2015
Primary completion :
01/21/2020
Completion :
11/17/2022
CD19 • TCF3
|
CD19 expression
|
Kymriah (tisagenlecleucel-T)
Phase 1
Nationwide Children's Hospital
Not yet recruiting
Last update posted :
02/09/2024
Initiation :
04/01/2024
Primary completion :
12/01/2026
Completion :
12/01/2027
CD19
|
CD19 positive • CD19 expression
|
cyclophosphamide
Phase 2
Memorial Sloan Kettering Cancer Center
Recruiting
Last update posted :
02/09/2024
Initiation :
07/12/2022
Primary completion :
07/01/2026
Completion :
07/01/2026
CD19 • IFNG
|
CD19 expression
|
Kymriah (tisagenlecleucel-T)
Phase 1
Stanford University
Recruiting
Last update posted :
02/08/2024
Initiation :
10/02/2023
Primary completion :
08/01/2025
Completion :
08/01/2025
CD19
|
CD19 expression
|
dasatinib • Tecartus (brexucabtagene autoleucel)
Phase 1
National Cancer Institute (NCI)
Active, not recruiting
Last update posted :
02/07/2024
Initiation :
10/25/2017
Primary completion :
05/22/2023
Completion :
09/06/2024
CD19
|
CD19 expression
|
Opdivo (nivolumab) • Yervoy (ipilimumab) • Blincyto (blinatumomab) • CS1002 (ipilimumab biosimilar) • ABP 206 (nivolumab biosimilar) • CMAB 819 (nivolumab biosimilar)
Phase 1
Fred Hutchinson Cancer Center
Recruiting
Last update posted :
02/06/2024
Initiation :
12/08/2022
Primary completion :
12/31/2024
Completion :
12/31/2025
CD19
|
CD19 expression
|
cyclophosphamide • Breyanzi (lisocabtagene maraleucel) • fludarabine IV • NKTR-255
Phase 1
Baylor College of Medicine
Recruiting
Last update posted :
02/02/2024
Initiation :
07/18/2023
Primary completion :
07/17/2026
Completion :
03/29/2040
CD20 • CD19 • CD22
|
CD19 expression • CD22 expression
|
cyclophosphamide • fludarabine IV • autologous TriCAR T • cyclophosphamide intravenous
Phase 2
Miltenyi Biomedicine GmbH
Recruiting
Last update posted :
02/01/2024
Initiation :
08/18/2021
Primary completion :
12/31/2024
Completion :
07/31/2027
BCL2 • CD19 • BCL6
|
CD19 expression • BCL6 rearrangement • BCL2 rearrangement
|
gemcitabine • Rituxan (rituximab) • oxaliplatin • bendamustine • Polivy (polatuzumab vedotin-piiq) • zamtocabtagene autoleucel (MB-CART2019.1)
Phase 1/2
UNC Lineberger Comprehensive Cancer Center
Recruiting
Last update posted :
01/31/2024
Initiation :
03/22/2012
Primary completion :
04/22/2026
Completion :
04/22/2041
ABL1 • BCR • CD19
|
CD19 positive • CD19 expression
|
cyclophosphamide • fludarabine IV • cyclophosphamide intravenous • iC9-CAR19 cells • rimiducid (AP1903)
Phase 2
Academic and Community Cancer Research United
Recruiting
Last update posted :
01/18/2024
Initiation :
01/04/2024
Primary completion :
12/30/2029
Completion :
12/30/2030
CD19 • CCND1
|
Chr t(11;14) • CCND1 overexpression • CD19 expression • Chr t(11;14)(q13;q32)
|
Venclexta (venetoclax) • lenalidomide • Monjuvi (tafasitamab-cxix)
Phase 2/3
Nektar Therapeutics
Recruiting
Last update posted :
01/09/2024
Initiation :
12/23/2022
Primary completion :
01/01/2027
Completion :
01/01/2029
CD19
|
CD19 expression
|
NKTR-255
Phase 1
Bioray Laboratories
Recruiting
Last update posted :
01/08/2024
Initiation :
04/25/2023
Primary completion :
01/20/2024
Completion :
03/15/2024
CD19
|
CD19 expression
|
BRL-201
Phase 1
Institute of Hematology and Blood Transfusion, ...
Recruiting
Last update posted :
01/04/2024
Initiation :
06/02/2021
Primary completion :
12/01/2024
Completion :
06/01/2025
CD19
|
CD19 positive • CD19 expression